Management of Patients with Genotype 3 Chronic Hepatitis C

Can we Change the Duration of Therapy?

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Based on the favourable response to peginterferon and ribavirin combination therapy, genotype 2 and genotype 3 HCV infections have been regarded until recently as a single entity. However, due to several factors, patients with genotype 3 HCV infection show consistently lower sustained virological response rates than those observed in patients with genotype 2 infection. Recently, week 4 on-treatment response emerged as the most relevant predictor of sustained virological response and it was suggested as the criterion on which to base the reduction of treatment length for patients infected with genotype 2 and 3 HCV. In the absence of a rapid virological response patients with genotype 3 HCV respond less well than genotype 2 patients, even after 24 weeks of treatment. Advanced liver damage is the most relevant adverse factor among the host- and virus-related factors that are associated with the absence of a rapid virological response or of a poor response after an early response in patients treated with either short or standard courses of antiviral therapy.

Original languageEnglish
Title of host publicationClinical Dilemmas in Viral Liver Disease
PublisherWiley-Blackwell
Pages88-93
Number of pages6
ISBN (Print)9781405179058
DOIs
Publication statusPublished - Mar 10 2010

Fingerprint

Chronic Hepatitis C
Genotype
Therapeutics
Infection
Ribavirin
Antiviral Agents
Viruses
Liver

Keywords

  • Advanced liver damage
  • Body mass index
  • Genotype 3
  • Rapid virological response
  • Sustained virological response

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Management of Patients with Genotype 3 Chronic Hepatitis C : Can we Change the Duration of Therapy? / Mangia, Alessandra; Piazzolla, Valeria; Andriulli, Angelo.

Clinical Dilemmas in Viral Liver Disease. Wiley-Blackwell, 2010. p. 88-93.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{925fca77af76420a908a6eb6a9463047,
title = "Management of Patients with Genotype 3 Chronic Hepatitis C: Can we Change the Duration of Therapy?",
abstract = "Based on the favourable response to peginterferon and ribavirin combination therapy, genotype 2 and genotype 3 HCV infections have been regarded until recently as a single entity. However, due to several factors, patients with genotype 3 HCV infection show consistently lower sustained virological response rates than those observed in patients with genotype 2 infection. Recently, week 4 on-treatment response emerged as the most relevant predictor of sustained virological response and it was suggested as the criterion on which to base the reduction of treatment length for patients infected with genotype 2 and 3 HCV. In the absence of a rapid virological response patients with genotype 3 HCV respond less well than genotype 2 patients, even after 24 weeks of treatment. Advanced liver damage is the most relevant adverse factor among the host- and virus-related factors that are associated with the absence of a rapid virological response or of a poor response after an early response in patients treated with either short or standard courses of antiviral therapy.",
keywords = "Advanced liver damage, Body mass index, Genotype 3, Rapid virological response, Sustained virological response",
author = "Alessandra Mangia and Valeria Piazzolla and Angelo Andriulli",
year = "2010",
month = "3",
day = "10",
doi = "10.1002/9781444319590.ch20",
language = "English",
isbn = "9781405179058",
pages = "88--93",
booktitle = "Clinical Dilemmas in Viral Liver Disease",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Management of Patients with Genotype 3 Chronic Hepatitis C

T2 - Can we Change the Duration of Therapy?

AU - Mangia, Alessandra

AU - Piazzolla, Valeria

AU - Andriulli, Angelo

PY - 2010/3/10

Y1 - 2010/3/10

N2 - Based on the favourable response to peginterferon and ribavirin combination therapy, genotype 2 and genotype 3 HCV infections have been regarded until recently as a single entity. However, due to several factors, patients with genotype 3 HCV infection show consistently lower sustained virological response rates than those observed in patients with genotype 2 infection. Recently, week 4 on-treatment response emerged as the most relevant predictor of sustained virological response and it was suggested as the criterion on which to base the reduction of treatment length for patients infected with genotype 2 and 3 HCV. In the absence of a rapid virological response patients with genotype 3 HCV respond less well than genotype 2 patients, even after 24 weeks of treatment. Advanced liver damage is the most relevant adverse factor among the host- and virus-related factors that are associated with the absence of a rapid virological response or of a poor response after an early response in patients treated with either short or standard courses of antiviral therapy.

AB - Based on the favourable response to peginterferon and ribavirin combination therapy, genotype 2 and genotype 3 HCV infections have been regarded until recently as a single entity. However, due to several factors, patients with genotype 3 HCV infection show consistently lower sustained virological response rates than those observed in patients with genotype 2 infection. Recently, week 4 on-treatment response emerged as the most relevant predictor of sustained virological response and it was suggested as the criterion on which to base the reduction of treatment length for patients infected with genotype 2 and 3 HCV. In the absence of a rapid virological response patients with genotype 3 HCV respond less well than genotype 2 patients, even after 24 weeks of treatment. Advanced liver damage is the most relevant adverse factor among the host- and virus-related factors that are associated with the absence of a rapid virological response or of a poor response after an early response in patients treated with either short or standard courses of antiviral therapy.

KW - Advanced liver damage

KW - Body mass index

KW - Genotype 3

KW - Rapid virological response

KW - Sustained virological response

UR - http://www.scopus.com/inward/record.url?scp=84886062128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886062128&partnerID=8YFLogxK

U2 - 10.1002/9781444319590.ch20

DO - 10.1002/9781444319590.ch20

M3 - Chapter

SN - 9781405179058

SP - 88

EP - 93

BT - Clinical Dilemmas in Viral Liver Disease

PB - Wiley-Blackwell

ER -